Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq, in what is being seen as a test of the appetite among investors for earlier-stage drug developers. The ...

Once hailed as the “gold standard” for cancer management, though, MDTs are now under strain. Over the years, the number of referrals have gone up drastically and meeting times have increased to up to ...

Patients are being recruited into a clinical trial of two potential therapies for the Bundibugyo species of Ebola in the Democratic Republic of the Congo (DRC), according to the World Health ...

This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum. PureTech's Celea eyes phase 3 for IPF drug a ...

Newron Pharmaceuticals thinks it may have reached an agreement with the FDA on a way to get the development of its schizophrenia candidate evenamide back on track, after it was placed under a clinical ...

Domenico wrote that drug pricing is remarkable for its "puzzling opacity," but added that it is "not necessary to unravel the ...

Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new agreement to develop drugs for ...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May, as organisations ...

Novartis has secured EU approval for Itvisma, a new intrathecal formulation of its spinal muscular atrophy (SMA) gene therapy ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...